Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010178462> ?p ?o ?g. }
- W3010178462 endingPage "2295" @default.
- W3010178462 startingPage "2288" @default.
- W3010178462 abstract "Background Adults with impaired performance status (PS) often receive immune checkpoint inhibitors (ICIs) for advanced non–small cell lung cancer (NSCLC) despite limited efficacy data and unknown effects on end‐of‐life care. Methods This was a retrospective, single‐site study of 237 patients with advanced NSCLC who initiated ICI treatment from 2015 to 2017. Cox regression was used to compare the overall survival (OS) of patients who had impaired PS (≥2) at the start of ICI treatment with those who had PS 0 or 1 using Cox regression. Logistic regression was conducted to analyze the association between ICI use in the last 30 days of life and the use of end‐of‐life health care. Results The patient mean age at ICI initiation was 67 years (range, 37‐91 years), and 35.4% of patients had PS ≥2. Most patients (80.8%) received ICI as second‐line or later therapy. The median OS was 4.5 months in patients with PS ≥2 and 14.3 months in those with PS 0 or 1 (hazard ratio, 2.5; P < .0001). Among the patients who died (n = 184), 28.8% who had PS ≥2 received ICIs in their last 30 days of life compared with 10.8% of those who had PS 0 or 1 ( P = .002). Receipt of ICI in the last 30 days of life was associated with decreased hospice referral (odds ratio, 0.29; P = .008) and increased in‐hospital deaths (odds ratio, 6.8; P = .001), independent of PS. Conclusions Adults with advanced NSCLC and impaired PS experience significantly shorter survival after ICI treatment and receive ICIs near death more often than those with better PS. Receipt of an ICI near death was associated with lower hospice use and an increased risk of death in the hospital. These results underscore the need for high‐quality communication about potential tradeoffs of ICIs, particularly among adults receiving ICIs as second‐line or later therapy." @default.
- W3010178462 created "2020-03-13" @default.
- W3010178462 creator A5000172075 @default.
- W3010178462 creator A5009871897 @default.
- W3010178462 creator A5017682074 @default.
- W3010178462 creator A5035343389 @default.
- W3010178462 creator A5055898059 @default.
- W3010178462 creator A5072358766 @default.
- W3010178462 creator A5078852708 @default.
- W3010178462 creator A5081227348 @default.
- W3010178462 creator A5085721289 @default.
- W3010178462 date "2020-03-06" @default.
- W3010178462 modified "2023-10-16" @default.
- W3010178462 title "Performance status and end‐of‐life care among adults with non–small cell lung cancer receiving immune checkpoint inhibitors" @default.
- W3010178462 cites W1967237446 @default.
- W3010178462 cites W2023888294 @default.
- W3010178462 cites W2037139573 @default.
- W3010178462 cites W2104347254 @default.
- W3010178462 cites W2115127702 @default.
- W3010178462 cites W2115156326 @default.
- W3010178462 cites W2119642155 @default.
- W3010178462 cites W2149577037 @default.
- W3010178462 cites W2154692607 @default.
- W3010178462 cites W2156353875 @default.
- W3010178462 cites W2198093519 @default.
- W3010178462 cites W2289990863 @default.
- W3010178462 cites W2343436732 @default.
- W3010178462 cites W2527905628 @default.
- W3010178462 cites W2567564314 @default.
- W3010178462 cites W2762777471 @default.
- W3010178462 cites W2796582438 @default.
- W3010178462 cites W2802509580 @default.
- W3010178462 cites W2891978472 @default.
- W3010178462 cites W2892640821 @default.
- W3010178462 cites W2901692833 @default.
- W3010178462 cites W2913035147 @default.
- W3010178462 cites W2937826446 @default.
- W3010178462 cites W2965486449 @default.
- W3010178462 cites W2982040065 @default.
- W3010178462 cites W2984096159 @default.
- W3010178462 cites W4210394199 @default.
- W3010178462 doi "https://doi.org/10.1002/cncr.32782" @default.
- W3010178462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32142165" @default.
- W3010178462 hasPublicationYear "2020" @default.
- W3010178462 type Work @default.
- W3010178462 sameAs 3010178462 @default.
- W3010178462 citedByCount "44" @default.
- W3010178462 countsByYear W30101784622020 @default.
- W3010178462 countsByYear W30101784622021 @default.
- W3010178462 countsByYear W30101784622022 @default.
- W3010178462 countsByYear W30101784622023 @default.
- W3010178462 crossrefType "journal-article" @default.
- W3010178462 hasAuthorship W3010178462A5000172075 @default.
- W3010178462 hasAuthorship W3010178462A5009871897 @default.
- W3010178462 hasAuthorship W3010178462A5017682074 @default.
- W3010178462 hasAuthorship W3010178462A5035343389 @default.
- W3010178462 hasAuthorship W3010178462A5055898059 @default.
- W3010178462 hasAuthorship W3010178462A5072358766 @default.
- W3010178462 hasAuthorship W3010178462A5078852708 @default.
- W3010178462 hasAuthorship W3010178462A5081227348 @default.
- W3010178462 hasAuthorship W3010178462A5085721289 @default.
- W3010178462 hasBestOaLocation W30101784621 @default.
- W3010178462 hasConcept C121608353 @default.
- W3010178462 hasConcept C126322002 @default.
- W3010178462 hasConcept C143998085 @default.
- W3010178462 hasConcept C151956035 @default.
- W3010178462 hasConcept C156957248 @default.
- W3010178462 hasConcept C167135981 @default.
- W3010178462 hasConcept C207103383 @default.
- W3010178462 hasConcept C2776256026 @default.
- W3010178462 hasConcept C2776907518 @default.
- W3010178462 hasConcept C44249647 @default.
- W3010178462 hasConcept C50382708 @default.
- W3010178462 hasConcept C71924100 @default.
- W3010178462 hasConceptScore W3010178462C121608353 @default.
- W3010178462 hasConceptScore W3010178462C126322002 @default.
- W3010178462 hasConceptScore W3010178462C143998085 @default.
- W3010178462 hasConceptScore W3010178462C151956035 @default.
- W3010178462 hasConceptScore W3010178462C156957248 @default.
- W3010178462 hasConceptScore W3010178462C167135981 @default.
- W3010178462 hasConceptScore W3010178462C207103383 @default.
- W3010178462 hasConceptScore W3010178462C2776256026 @default.
- W3010178462 hasConceptScore W3010178462C2776907518 @default.
- W3010178462 hasConceptScore W3010178462C44249647 @default.
- W3010178462 hasConceptScore W3010178462C50382708 @default.
- W3010178462 hasConceptScore W3010178462C71924100 @default.
- W3010178462 hasIssue "10" @default.
- W3010178462 hasLocation W30101784621 @default.
- W3010178462 hasOpenAccess W3010178462 @default.
- W3010178462 hasPrimaryLocation W30101784621 @default.
- W3010178462 hasRelatedWork W2064573700 @default.
- W3010178462 hasRelatedWork W2554284703 @default.
- W3010178462 hasRelatedWork W2745828203 @default.
- W3010178462 hasRelatedWork W2967366602 @default.
- W3010178462 hasRelatedWork W2981696006 @default.
- W3010178462 hasRelatedWork W2994686985 @default.
- W3010178462 hasRelatedWork W3009186173 @default.
- W3010178462 hasRelatedWork W3213778696 @default.